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A B S T R A C T
Despite the fact that 80% of adult acute myeloid leukaemia patients reach complete morphological remission
after induction chemotherapy, many of them relapse. Many studies have shown that detection of minimal re-
sidual disease (deﬁned as ‘any detectable evidence of persistent leukaemic cells during complete morphological
remission’) has an added value in prediction of relapse and survival, and is more than just a surrogate marker for
already known risk factors in AML. As such, the behaviour of the disease during treatment might become equally
or even more important to decide whether or not an upgrade of treatment (such as an allogeneic stem cell
transplantation) is necessary to improve outcome. However, there are still many open issues as to what the ideal
time point is to measure MRD, which threshold is clinically signiﬁcant, what sample (peripheral blood or bone
marrow) should be used and how we can standardize tests so that results from diﬀerent labs become comparable.
This review gives an overview of currently available evidence regarding technical issues, prognostic impact and
MRD-directed treatment in AML.
1. Introduction
Despite the fact that 80% of adult acute myeloid leukaemia (AML)
patients reach complete morphological remission (CR) after induction
chemotherapy, many of them relapse, with a 5-year overall survival
(OS) of only 30–40%. Relapse is the result of incomplete eradication of
disease, clonal evolution from preleukaemic clones, or therapy-related
mutagenesis. To date, remission in clinical studies has been deﬁned as
purely morphological remission (< 5% blasts on bone marrow), but
during the past decades, new much more sensitive techniques have
been developed to detect minimal or measurable residual disease
(MRD), which is deﬁned as ‘any detectable evidence of persistent leu-
kaemic cells below the threshold of complete morphological remission’
(Terwijn et al., 2013; Benton and Ravandi, 2017).
MRD already has an established role in several haematological
malignancies such as chronic myeloid leukaemia (CML), acute lym-
phoblastic leukemia (ALL) and acute promyelocytic leukemia (APL),
where it impacts on treatment decisions, such as therapy switch, con-
solidation with/without allogeneic stem cell transplantation (alloSCT)
and administration of pre-emptive therapy. In non-APL AML however,
although extensive data is available on the prognostic impact of MRD
during the course of intensive chemotherapy, it does not yet routinely
determine post-induction treatment strategies (i.e. chemotherapy/au-
tologous stem cell transplantation versus allogeneic stem cell trans-
plantation), which is nowadays mainly based on pre-treatment leu-
kaemia-speciﬁc characteristics, such as cytogenetics and a limited
number of molecular aberrations. Nor is there evidence to guide pre-
emptive therapy in case of molecular relapse, as is the case for APL.
In this review we discuss some technical aspects of MRD and pro-
vide an overview of what is currently known about the prognostic
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impact of MRD during AML treatment, and its possible impact on
treatment decisions.
2. Technical aspects of MRD detection
Diﬀerent techniques for detecting low amounts of residual leu-
kaemic cells are available: multiparameter ﬂow cytometry (MFC) fol-
lowing a known ‘leukaemia-associated immunophenotype’ (LAIP)
during therapy, or searching for ‘diﬀerent-from-normal’ (DFN) popu-
lations (sensitivity up to 10E-4 to 10E-5, available in ∼80% of pa-
tients); (q)RT-PCR detecting speciﬁc molecular abnormalities and
quantifying abnormal leukaemic gene transcripts in comparison to
normal genes in the same sample (sensitivity up to 10E-4 to 10E-5,
available for 60–70% of patients); mutational analysis e.g. by next-
generation sequencing (NGS); FISH and karyotyping; as well as gene
expression proﬁling (e.g. WT1 overexpression).
Each technique has its own advantages and limitations, which
makes the choice for the most informative approach for each AML
subtype, challenging. They all diﬀer in terms of sensitivity, applic-
ability, complexity and the ability to evaluate clonal evolution. To keep
in mind, MRD is never 100% reliable: false-negative MRD could be the
result of immunophenotypic changes, residual leukaemic cells hiding in
diﬃcult-to-sample micro-environments, bone marrow sample hemodi-
lution, the small number of residual leukaemic cells, clonal evolution,
the loss of a speciﬁc mutation. On the other hand, some positive MRD-
values need to be interpreted with caution too: residual CBFB-MYH11-
transcripts might represent a preleukaemic clone, ﬂow cytometry might
detect a regenerating clone with a diﬀerent-from-normal phenotype,
residual mutations such as DNMT3A, ASLX1, TET2 could reﬂect CHIP
(clonal haematopoiesis of indetermined potential, which is not always
associated with a higher risk of relapse and can be detected in long-term
remission) (Jongen-Lavrencic et al., 2018; Mosna and Gottardi, 2016).
A very important discussion related to MRD, concerns the questions
about the optimal cut-oﬀ and the ideal time point to measure MRD. For
MFC and diﬀerent leukaemia-speciﬁc RT-qPCR assays (fusion tran-
scripts and mutations like NPM1), many studies have deﬁned particular
threshold levels or ‘cut-oﬀ’ values that are predictive for outcome at
various time points. However, these cut-oﬀ values are not universally
applicable. A general problem is the fact that many of the techniques
are not yet standardized between laboratories. Therefore, it is diﬃcult
to compare results between diﬀerent studies, or to implement the re-
sults from studies in the daily practice in one’s own routine lab.
For RT-qPCR assays, this issue could be solved by reporting relative
values (compared to diagnostic samples), as this will correct for
methodological diﬀerences between laboratories. Moreover, at diag-
nosis, absolute values of several markers repeatedly failed to correlate
with outcome (Schnittger et al., 2009; Krönke et al., 2011; Yin et al.,
2012; Corbacioglu et al., 2010; Perea et al., 2006; Pigazzi et al., 2015;
Zhang et al., 2013). Also during therapy, Hubmann et al. found that
NPM1 kinetics, but not absolute levels, were signiﬁcant prognostic in-
dicators for relapse risk (Hubmann et al., 2014). Similar results were
found for t(8;21)-AML (Yin et al., 2012; Pigazzi et al., 2015; Jourdan
et al., 2013): for example, in the MRC-AML15 trial, where log reduction
of BM RUNX1-RUNX1T1-transcripts was more prognostic than absolute
copy numbers in an adjusted regression analysis.
In MFC as well, diﬀerent methods are used to quantify the MRD
burden (relative to CD45+ leukocytes or CD34+ cells or total viable
cells; correction for percentage LAIP-positive blasts at diagnosis). To
harmonize reporting, the ELN guidelines recommend to relate LAIP
events to the CD45+ leukocytes (excluding CD45- erythroblasts)
(Schuurhuis et al., 2018).
In addition, the ideal time point to measure MRD is yet unclear. The
time point at which MRD is most discriminatory might diﬀer depending
on the marker or AML subtype, and might be dependent on what it will
be used for: MRD at early time points may impact post-remission
treatment, MRD during follow up could trigger pre-emptive therapy.
Finally, the preferred sample type is under discussion. Peripheral
blood (PB) has certain practical advantages over bone marrow (BM),
and some studies show signiﬁcant concordance between the two sample
types (Maurillo et al., 2007; Zeijlemaker et al., 2016). However, PB is
characterized by a lower MRD burden, and correlation with BM results,
as well as applicability for outcome prediction may depend on the
target analyzed and the time point of the analysis.
A recent report by the MRD working party of the ELN provides an
overview of the studies that have been published for several markers,
with detailed recommendations regarding technical aspects and re-
porting of MRD results (Schuurhuis et al., 2018).
In conclusion, for every diﬀerent marker, a clinically meaningful
time point, threshold and sample type needs to be carefully determined
before implementing MRD in daily clinical practice. This will be dis-
cussed in detail for several markers.
Table 1
Key messages on clinical impact of MRD.
Clinical impact of MRD: take home messages
NPM1
During aplasia after the 1st induction, a 1-log reduction in BM-MRD is informative on
relapse risk, independent of other risk factors.
There is convincing (retrospective) evidence that presence of PB-MRD after 2 cycles is
an independent negative prognostic factor that can even overrule pre-treatment
risk factors such as WBC count, DNMT3A or FLT3 status.
During follow up, persistence of NPM1 mutation is possible in long-term remission,
albeit at low copy numbers, and most of the patients return negative on
subsequent samples.
One log rise in MRD predicts a haematological relapse.
As BM-MRD is 1 log more sensitive than PB-MRD, BM-samples are preferred in
follow-up phase after the end of treatment, although it has not been shown to
improve outcome yet
NPM1 seems stable as MRD marker, but clonal evolution from an ancestral clone
without NPM1 mutation is possible, as well as evolution to NPM1-negative MDS/
MPN.
Inv(16)
High copy numbers after the 1st cycle are associated with a high relapse rate.
Two negative BM-MRD samples during consolidation and early follow-up (3 months)
is associated with a high probability of continuing CR.
Persistent low-level MRD positivity is possible in long-term remission, reﬂecting a
silent pre-leukaemic clone.
As there is more data on the value of absolute transcript levels, more eﬀorts are
necessary to standardize MRD testing, and/or more research is needed on MRD
kinetics.
t(8;21)
More than 3-log reduction after the 2nd cycle is associated with very low risk of
relapse.
BM-MRD negativity after treatment is not a prerequisite for continued remission. In
contrast, PB-MRD is more predictive for relapse after treatment.
Median time to haematological relapse after MRD conversion is 4-5 months.
Multiparameter ﬂow cytometry
Already at early time points during therapy, MFC-MRD is highly predictive for
outcome, however, the most discriminatory time point has not been identiﬁed
yet.
A cut-oﬀ of 0.1% can be used to deﬁne MRD negative versus positive.
Adding MFC- MRD to known risk factors can change prognostic categories.
Adding information on leukaemic stem cells to MFC-MRD after the 2nd cycle further
improves prognostication.
Next generation sequencing
The use of special, more sensitive NGS techniques is a prerequisite to analyze MRD.
Not all genes have the same impact on prognosis: persistence of DTA-mutations
(DNMT3A, TET2 and ASXL1) is not correlated with higher relapse rate. In
contrast, persistence of non-DTA mutations during complete remission has
negative prognostic impact on relapse and survival.
A clear threshold still has to be determined.
NGS MRD cannot be applied on patients with recurrent translocations, where MRD is
still best detected using qPCR.
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3. Clinical impact of MRD detection (Table 1)
3.1. NPM1 mutations
NPM1 mutation is present in 25–30% of AML, and 45–60% of
normal karyotype AML, which makes it a very useful tumour marker in
AML. This is reﬂected by the presence of many, although all retro-
spective, papers on the subject. The absolute NPM1 mutation level at
diagnosis does not seem to predict outcome (Schnittger et al., 2009;
Krönke et al., 2011), but already early in the induction phase, during
aplasia (day 16–18) after the 1st cycle, MRD kinetics do. Despite the fact
that virtually all patients remain MRD positive at this point, more than
1-log reduction in BM-NPM1 is associated with a lower cumulative
incidence of relapse (CIR) within 100 days, even after correcting for
ELN risk classiﬁcation (Hubmann et al., 2014). Another study could not
show absolute values of NPM1 transcripts to be predictive of CIR, nor
OS, at this time point (Krönke et al., 2011).
MRD after two cycles has been identiﬁed as the most important time
point in NPM1-AML by diﬀerent research groups.(Krönke et al., 2011;
Hubmann et al., 2014; Ivey et al., 2016; Balsat et al., 2017) At this time
point, kinetics are independent prognostic for relapse incidence:< 3-log
reduction of BM-NPM1 was identiﬁed by Hubmann et al. as a sig-
niﬁcant threshold with a positive predictive value for relapse of 65%
and negative predictive value of 74%, independent from ELN risk
classiﬁcation, WBC count and LDH on multivariate analysis (Hubmann
et al., 2014). A French group found that the presence of PB-MRD after
two cycles had predictive power, with less than 4-log reduction being
associated with a higher relapse incidence (3Y CIR 65.8% versus
20.5%) and lower OS (40.8% versus +/- 92%). This was independent
of pre-treatment variables such as abnormal karyotype, and FLT3-ITD
status (Balsat et al., 2017). Hence, both research groups showed that
MRD at this time point adds valuable information to the already
known pre-treatment risk factors for predicting relapse and survival.
Even more striking are the ﬁndings of Ivey et al., who found the
presence of PB-MRD for NPM1 after 2 cycles to be the only prognostic
factor for relapse, independent of WBC count, DNMT3A status or FLT3
status, and the sole prognostic factor for mortality, independent of WBC
count, thereby even overruling pre-treatment risk factors (Ivey et al.,
2016). Similar ﬁndings are seen in the paper by Hubmann et al. who
showed BM-MRD kinetics (3-log reduction) after induction to be the
sole prognostic risk factor for relapse (not OS) in a multivariate analysis
with ELN risk category, age and WBC count (Hubmann et al., 2014).
In addition, Ivey et al. showed that within the group of patients with
high risk mutations such as DNMT3A and/or FLT3-ITD, the absence of
NPM1 PB-MRD (with a sensitivity of at least 0.01%) after two cycles
identiﬁed a subgroup of patients with favorable outcome (survival
76%). Also, in the absence of these mutations, the presence of PB-MRD
after two cycles was associated with very poor outcome (Ivey et al.,
2016). Although not yet tested in a prospective randomized trial, these
ﬁnding clearly challenge our current transplant indications.
At the end of treatment, presence of BM-MRD is associated with an
increased risk of relapse and decreased OS (Krönke et al., 2011;
Lambert et al., 2014). However, during follow-up, low levels of BM-
NPM1 can be present in long-term CR patients. In the study of Krönke
et al., 51% of 136 patients had at least 1 positive follow-up sample
(BM), with 1 in three patients remaining in CR with a median follow-up
of 24.8 months (range 1.8–80.5). All had low levels and the majority
turned negative in one of the following samples (Krönke et al., 2011).
Nevertheless, 1-log increase in BM-NPM1 transcripts is associated
with clinical relapse, within a median time of 60–133 days (Schnittger
et al., 2009; Krönke et al., 2011; Ivey et al., 2016). Therefore, it seems
wise to analyse BM-MRD after treatment every 2–3 months for 18–24
months. However, it has not yet been established whether treating early
molecular relapse is associated with a survival beneﬁt, nor which kind
of pre-emptive treatment would be preferred. Moreover, there is still
some discussion on the stability of NPM1 as MRD marker. Data from the
literature are ambiguous. In the study of Ivey et al., NPM1 mutation
was lost in only 1 in 70 relapsed patients, whereas Hubmann et al.
described 3 in 45 patients who lost NPM1 (Hubmann et al., 2014; Ivey
et al., 2016). Relapse can occur from the initial AML clone, but also
from an ancestral clone, with or without clonal evolution (Krönke et al.,
2013), leading to NPM1-negative relapses. On the other hand, devel-
opment of myelodysplastic syndromes or myeloproliferative disease
without NPM1 mutation has been described as well. In the paper of Ivey
et al., patients were young, and the phenomenon of preleukaemic
clones and CHIP is more rare in this population. This could explain the
stability of NPM1 as an MRD marker in their population.
Finally, there is the question whether peripheral blood should be
preferred over bone marrow for MRD-analysis. After reviewing the
literature, the answer depends on the time point of the MRD-analysis.
Krönke et al. show a higher sensitivity of BM-MRD during the early
time points, because 46% of the MRD-negative PB-samples had a
paired positive BM-sample (Krönke et al., 2011). However, they did not
correlate these ﬁndings with outcome. Ivey et al. did and could show
that - although less sensitive - PB-MRD at early time points was more
discriminatory for relapse and OS (Ivey et al., 2016). In contrast,
during follow-up, Ivey et al. showed that BM-MRD was 1 log more
sensitive than PB (Ivey et al., 2016). Therefore, one could state that
MRD testing in BM ànd PB is preferred during treatment, in contrast to
the follow-up phase, where BM is still more sensitive.
3.2. Core-binding factor-AML (CBF-AML)
CBF consists of a group of transcription factors that are involved in
normal haematopoiesis. Inv(16) and t(8;21) lead to loss of function of
this complex, resulting in diﬀerentiation blockade. These leukaemias
are generally chemo-sensitive, but nonetheless, 30% will relapse. MRD
can potentially identify those CBF-AML patients with high risk of re-
lapse, who might beneﬁt from a therapeutic upgrade, such as an allo-
geneic stem cell transplantation in ﬁrst complete remission.
3.2.1. CBFB-MYH11 or inv(16)
Pre-treatment copy numbers (CN) are not informative on CR, CIR or
OS (Yin et al., 2012; Corbacioglu et al., 2010; Perea et al., 2006). At the
early time points during therapy, there is some evidence that molecular
MRD informs on outcome and can be used to adjust treatment strate-
gies. Based on solid data in more than 100 patients, Yin et al showed in
a prospective study that PB-CBFB-MYH11 CN > 10/10E5 ABL1 copies
after the 1st cycle was predictive of relapse and survival (e.g. with a CIR
21% if< 10 CN and 100% if CN > 500) in multivariate analysis. (Yin
et al., 2012). In contrast, other authors could not conﬁrm these ﬁndings
in smaller series (Corbacioglu et al., 2010; Perea et al., 2006; Pigazzi
et al., 2015; Qin et al., 2015).
Later during consolidation, diﬀerent studies identiﬁed thresholds
informative for relapse incidence and/or mortality (e.g. PB CN > 10
(Yin et al., 2012)or 3-log reduction (Qin et al., 2015) after the 3rd
cycle). In a study by Corbacioglu and colleagues, evaluating MRD in
prospective German-Austrian AML Study Group treatment trials, pa-
tients with at least two PCR-negative BM-MRD during consolidation
and early (3 months) follow up, have the highest probability of re-
maining in CR, with a 90% relapse-free survival rate (Corbacioglu et al.,
2010).
During follow-up, persistence of inv(16) has been described in pa-
tients in long-term remission: in the series of Corbacioglu et al., 11 out
of 35 patients in continuing CR had positive PCR, albeit with low copy
numbers (Corbacioglu et al., 2010). This could be explained by the
‘two-hit theory’ of AML ontogenesis: in this model, the CBF transloca-
tion is the ‘1st hit’, leading to impaired diﬀerentiation and giving rise to
a preleukaemic phase, that might remain clinically silent until true
leukaemia develops after a ‘2nd hit’, being a mutation/genetic aberra-
tion leading to excessive proliferation (e.g. KIT or RAS mutations)
(Mosna and Gottardi, 2016). Thus, persistent PCR-positivity is possible
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during follow-up, and does not need therapeutic intervention per se.
Therefore, Ivey et al. and Corbacioglu et al. identiﬁed critical MRD
thresholds in both BM and PB above which relapse occurs (BM CBFB-
MYH11>50/10E5 ABL1 copies or PB CBFB-MYH11>10/10E5 ABL1
copies). (Corbacioglu et al., 2010; Ivey et al., 2016). However, due to
lack of standardization (as mentioned above), implementation of those
cut-oﬀs into your own clinical practice remains challenging. But as a
general rule, it can be stated that conversion from negative to positive
PCR and ≥ 1 log rise in PCR levels are predictive of imminent relapse
(Corbacioglu et al., 2010; Lane et al., 2009).
Finally, on the question of what source of samples to use,
Corbacioglu et al. showed higher sensitivity of bone marrow samples
during therapy, whereas peripheral blood samples were equally in-
formative in follow up (Corbacioglu et al., 2010).
3.2.2. RUNX1-RUNX1T1 or t(8;21)
Diﬀerent study groups showed in pediatric patients that absolute
values of RUNX1-RUNX1T1-transcripts during treatment do not corre-
late with outcome, but log-reduction does (Yin et al., 2012; Jourdan
et al., 2013; Zhu et al., 2013). These ﬁndings however, could not be
conﬁrmed in a multivariate analysis, probably because of lack of power.
The prospective CBF-2006 trial (ALFA group) identiﬁed the time point
before 2nd consolidation as the only point of prognostic value,
with< 3-log reduction being associated with worse prognosis, which
was more powerful than the identiﬁcation of cKIT mutations (Jourdan
et al., 2013). In this trial, a transplant was oﬀered to poor MRD-re-
sponders, but the study was not designed to demonstrate whether al-
logeneic SCT could overcome this poor prognosis and improve survival.
Moreover, failing to achieve a 3-log reduction in RUNX1-RUNX1T1
after the second consolidation could also discriminate high-risk patients
in the prospective studies of Zhu et al (AML05 trial) (Zhu et al., 2013)
and Yin et al (MRC AML-15 trial) (Yin et al., 2012).
At the end of treatment, only 30% of patients reach complete mo-
lecular remission in bone marrow (Willekens et al., 2016) and a sig-
niﬁcant portion of t(8;21)-patients remains positive during a long time
without a haematological relapse (e.g. 9% of all patients after up to 2
years of follow up according to Yin et al. (Yin et al. (2012))). This
probably reﬂects persistence of RUNX1-RUNX1T1 positive non-leu-
kaemic cells such as haematopoietic stem cells, B cells, monocytes and/
or mast cells. However, values of BM- and PB-MRD are consistently
lower in patients in continued remission (Jourdan et al., 2013), and
conversion of MRD negativity to positivity during follow-up is asso-
ciated with a high risk of relapse, after a median of 4–5 months(Yin
et al. (2012); Jourdan et al., 2013). During follow-up bone marrow is
more sensitive than peripheral blood, but only PB-MRD is predictive for
relapse (Willekens et al., 2016): i.e. the latter is more discriminatory.
To date, it is not clear at what time point and at which level of MRD,
treatment should be upgraded. We keep in mind that a high percentage
of CBF-AML patients can be salvaged with rescue chemotherapy, which
makes it diﬃcult to correlate MRD to survival. It is not yet clear whe-
ther allogeneic SCT in CR1 is improving outcome in good risk AML with
poor MRD response.
4. Multiparameter ﬂow cytometry
Residual leukaemic cells can be identiﬁed by MFC using ‘leukaemia-
associated immunophenotypes’ (LAIP) or ‘diﬀerent-from-normal ap-
proach’ in the majority of the patients (∼80%). The ﬁrst is based on
patient-speciﬁc antibody panels that are deﬁned at diagnosis and used
during follow up, the latter is based on the identiﬁcation of an aberrant
diﬀerentiation and maturation pattern in follow-up. It is recommended
to combine both approaches to deﬁne MRD, allowing detection of im-
munophenotype shifts and monitoring patients for which information
from diagnosis is not available. By using suﬃciently large panels of
antibodies (minimum 8 colors) and same tubes at diagnosis and at
follow-up, both approaches can be combined (Schuurhuis et al., 2018).
The recently published consensus document on MRD from the ELN
provides an excellent overview of the most important studies on the
prognostic value of MRD by MFC (Schuurhuis et al., 2018). With sig-
niﬁcant cut-oﬀ levels between 0.035% to 0.2%, a general cut-oﬀ of
0.1% was found to be most relevant to distinguish MRD-positive from
MRD-negative patients (Schuurhuis et al., 2018), although there is still
some discussion on this subject. The threshold is possibly dependent on
the time point of collection.
At present, the prognostic signiﬁcance of MFC-MRD has been es-
tablished by many diﬀerent study groups, with a clear advantage for
risk analysis at early time points. As it might be diﬃcult to discriminate
true MRD based on LAIP from regenerating haematopoietic cells, the
phase of aplasia after the ﬁrst induction might be the ideal moment for
MFC-MRD. Könkhe et al. showed that MRD positivity at day 15 post-
induction is an independent risk factor for RFS and OS, independent of
age or cytogenetic risk. They could not demonstrate additional value
from MRD at the end of induction (Köhnke et al., 2015). This was in
contrast to Freeman et al, who prospectively identiﬁed the time point
after the 1st induction as the most informative one in patients> 60
years, independent of other pre-treatment risk factors. (Freeman et al.,
2013). In addition, Terwijn et al. prospectively showed that MRD after
the 1st cycle, the 2nd cycle and even during consolidation, is prognostic
for relapse incidence, RFS and OS, mainly during the ﬁrst year, and
much less for relapse beyond one year (Terwijn et al., 2013).
The load of leukaemic stem cells (LSC) at diagnosis has been proven
to be of prognostic value in both adults and children (Hanekamp et al.,
2017). Adding information on the presence or absence of LSC to MFC-
MRD after the 2nd cycle improves prognostication with MRD-pos/LSC-
pos patients having the worst prognosis with 100% 3Y CIR and 100%
3Y mortality (in contrast to resp. 35% and 66% for MRD-neg/LSC-neg
patients). This added value was conﬁrmed in a multivariate analysis,
correcting for all known risk factors, including HOVON risk group and
post-remission treatment (Zeijlemaker et al., 2017).
Although retrospective, Buccisano et al. clearly showed that MFC-
MRD-positive good- and intermediate-risk AML behave as bad as poor-
risk and FLT3-positive AML with regard to RFS and OS. On the other
hand, MRD-negative good risk and intermediate risk have a similar
outcome, concluding that the combination of pre-treatment factors and
post-consolidation quality of response improves the deﬁnition of
prognostic categories (Buccisano et al., 2010).
BM-MFC is preferred above PB-MFC because of a higher sensitivity,
although pre-analytical issues are of great concern. As larger amounts
of bone marrow are aspired to allow analysis of more events (up to
10E7), there is a higher risk of dilution with PB and subsequent loss of
sensitivity, unless the ﬁrst portion of the aspirate is used.
5. Next generation sequencing (NGS)
MRD detection by qPCR analysis and ﬂow cytometry have proven
their use in AML. However, there is still an portion of patients that lack
a traceable marker, and clonal evolution or phenotypic switching limits
the use of current MRD techniques. NGS could ﬁll this gap as a broad
variety of mutations are detected (Cruz et al., 2017).
After the ﬁrst sequencing of an AML genome in 2008 (Ley et al.,
2008), several other NGS projects demonstrated that AML is char-
acterized by a low number of mutations, with∼25 frequently mutated
genes. The number of mutations per patient depends on the gene set
analyzed and ranges from 3 to 12 (Jongen-Lavrencic et al., 2018; Hirsch
et al., 2017; Klco et al., 2015) and in most studies, ≥90% of patients
have at least one mutation, demonstrating the theoretical applicability
of NGS to detect MRD in a large group of patients. Moreover, a com-
bined analysis of several markers could circumvent the false-negative
results that are sporadically seen when only a single target is analyzed.
The introduction of MRD detection by NGS was hampered by the lim-
ited sensitivity (1–5%) when large gene panels are used. A recent report
solves this problem by performing MRD with targeted deep sequencing
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in a patient-tailored analysis (Malmberg et al., 2017). The analysis of a
patient-speciﬁc set of genes, where mutations were detected at diag-
nosis, enables a very high coverage (and sensitivity) of these regions at
an acceptable cost. Other groups use error-corrected NGS with unique
molecular identiﬁers (UMI) (Hirsch et al., 2017; Young et al., 2016).
UMI’s are random DNA-barcodes that are attached to individual DNA
fragments before the ﬁrst ampliﬁcation reaction. When variants are
only detected in fragments containing the same barcode, this variant is
most likely due to a technical error, introduced during PCR ampliﬁca-
tion. Only when the same variant is found in fragments with diﬀerent
barcodes, it can reliably be called as a true positive variant. The use of
UMI’s thus increases the discriminatory power between true positive
variants and sequencing artefacts, increasing the sensitivity of the
assay. A third approach uses statistical methods to reliably discriminate
true positives from sequencing background noise (Jongen-Lavrencic
et al., 2018).
The existence of age-related CHIP in elderly individuals complicates
the MRD analysis, as it has been shown that patients in remission can
show even high levels of these mutations, which are not necessarily
associated with an increased chance of relapse. Additionally, the clin-
ical context in which the NGS analysis is performed is critical for a
correct interpretation. In theory, CHIP mutations are not good targets to
detect MRD, although in the context of alloSCT, such mutations could
have potential interest (Hirsch et al., 2017), as also these mutations will
be cleared by a successful treatment.
While early reports showed the applicability of NGS to detect MRD
in single genes, more recent publications use an unbiased approach and
detect multiple mutations in one analysis. For instance, in a pro-
spective, single center study of 50 patients where genome analysis was
done at diagnosis and 30 days after successful induction therapy, almost
half had one or more persistent leukaemia-associated mutations
(> 2.5% allelic frequency) at remission (Klco et al., 2015). These pa-
tients showed reduced EFS and OS when compared to the group that
did not show persistent mutations. Another prospective study of 69
patients could only detect a signiﬁcant impact on LFS and OS when
more than one mutation was present above the threshold (0.4%) when
the patient was in CR (Hirsch et al., 2017).
A recent, larger study of 482 patients with a 54-gene panel detected
an average of 2.9 mutations per patient (Jongen-Lavrencic et al., 2018).
Similar to the smaller studies described above, half of the patients
showed persistent mutations during CR (51.4%) and these were most
common in DNMT3A, TET2 and ASXL1 (abbreviated as DTA), genes
known to be frequently mutated in patients with CHIP (Hirsch et al.,
2017; Acuna-Hidalgo et al., 2017). The frequency of the persistent
mutations ranged from 0.02% to 47%, with higher allele frequencies for
the DTA mutations. It has been suggested before that this can be ex-
plained by the expansion of non-leukaemic clones that repopulate the
bone marrow after induction therapy (Wong et al., 2016). The detection
of persistent DTA mutations alone during CR was not correlated with an
increased risk of relapse. However, persistent non-DTA mutations were
seen in 28.4% of patients and this was associated with a signiﬁcantly
higher relapse rate (4-year relapse rate of 55.7% with detection vs
34.6% without detection), and with a lower 4-year RFS and OS. This
signiﬁcance was retained in a multivariate analysis that accounted for
the major relevant prognostic factors (Jongen-Lavrencic et al., 2018).
These papers show promising data for the use of NGS to detect MRD,
but further delineation of the threshold and which genes to include in
the algorithm seems necessary.
6. Combination of diﬀerent MRD techniques
Whatever the technique used, an important percentage of MRD-
negative patients still relapse. Combining diﬀerent techniques for MRD
monitoring will probably improve prognostication. Perea at al. com-
bined MFC (≤0.1%) with CBF-transcript levels (< 10 CN) at the end of
treatment to identify a patient group with excellent outcome (Perea
et al., 2006). Similar results were described by other authors, especially
in case PCR results were not very low or high (and therefore less in-
formative). Recently, Jongen-Lavrencic et al. combined the results from
the NGS-MRD analyses described above, with MFC for a group of 340
patients (Jongen-Lavrencic et al., 2018). Concordant results were found
in 69.1% of patients. However, 64 NGS positive patients did not show
MFC-MRD, and 41 MFC positive patients did not show NGS-MRD. Pa-
tients that showed MRD in both NGS and MFC showed the highest 4-
year relapse rate (73.3%). When only one method was positive, similar
relapse rates were seen for NGS and MFC-positive patients (52.3% and
49.8%, respectively). Patients for whom neither of the assays was po-
sitive had the lowest relapse rate (26.7%) (Jongen-Lavrencic et al.,
2018). These data show that combining of MRD techniques results in
reﬁnement of prognostication.
7. Implications for treatment
7.1. Eﬀect of treatment on MRD
Several studies show that intensifying chemotherapy (e.g. re-
inforced induction in CBF-2006 trial, addition of Clofarabine to stan-
dard chemotherapy in HOVON102 study or addition of gemtuzumab
ozogamycin in the ALFA0701-study) leads to a better quality of re-
mission in patients in CR (i.e. more rapid decline in MRD and/or more
MRD-negative patients), sometimes (but not every time) resulting in
better outcome (Jourdan et al., 2013; Lambert et al., 2014; Löwenberg
et al., 2017). These data suggest that MRD might be a reasonable
candidate to be a surrogate marker for survival. Using MRD as surrogate
endpoint could speed up approval of new drugs, but for now, the evi-
dence is not yet strong enough.
7.2. Impact of MRD on treatment
Currently, there are no prospective randomized controlled trials
proving that MRD-directed treatment improves outcome. However, in
daily practice and in certain study protocols, MRD is already used, for
example to decide on alloSCT in CBF-AML (Jourdan et al., 2013).
However, and especially for CBF-AML, we need to be cautious about
this, because survival is not always compromised by relapse in this
chemo-sensitive group, thanks to highly eﬀective salvage regimens:
e.g. < 3-log reduction in t(8;21)-AML is predictive for relapse risk
(with a CIR of 30% vs 4%), but not predictive for 5Y OS (Yin et al.,
2012). AlloSCT on the other hand will not necessarily improve outcome
in poor MRD-responders due to the important treatment-related mor-
tality. Prospective randomized trials could answer this question, but are
not available yet. However, there is some retrospective data supporting
the strategy of alloSCT for poor MRD-responders. Buccisano et al.
clearly showed a beneﬁt of alloSCT over autologous SCT or che-
motherapy in MRD-positive good- and intermediate-risk AML patients,
but not for MRD-negative patients (Buccisano et al., 2010). Similar
results were seen by Qin et al., who showed a beneﬁt from alloSCT for
inv(16) patients with poor MRD-response: 3Y-CIR 7.1% vs 87.7%, DFS
86.7% vs 12.3% and OS 93.3% vs 40.0%, all highly signiﬁcant. Again,
this could not be shown for good MRD-responders (Qin et al., 2015).
For NPM1-positive patients, the ALFA group retrospectively demon-
strated an added value of transplantation in patients with less than 4-
log reduction in PB-MRD after induction (1 or 2 cycles), but not in those
with> 4-log reduction. (Balsat et al., 2017). The only prospective study
on MRD-directed treatment is the one by Zhu et al. in t(8;21)-AML, in
which allogeneic SCT was oﬀered to patients not reaching 3-log re-
duction in transcript levels after the second consolidation, or losing
MRD-negativity within 6 months after the 2nd consolidation (deﬁned as
‘high risk’) (Zhu et al., 2013). However, this study is also at high risk of
bias because of a lack of randomization: MRD-directed treatment was
proposed for all patients, but many patients did not follow the study
proposal. Patients undergoing the proposed MRD-directed treatment
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were compared with those who did not undergo the proposed treatment
because of patient’s choice. AlloSCT was shown to improve relapse risk,
DFS and OS in high-risk patients (CIR 22.1% vs 78.9%; DFS 61.7% vs
19.6% and OS 71.6% vs 26.7%, all signiﬁcant), but not for low-risk
patients (Zhu et al., 2013). However, as all of the above studies were
retrospective and/or non-randomized studies, with a high risk of bias,
we need to conclude that there is still not enough evidence to support
MRD-directed treatment in AML.
Another question that has not been addressed properly so far is the
value of MRD-monitoring in follow-up post-therapy. In most AML
subtypes, there is a delay of a few months between the molecular and
haematological relapse. Theoretically, this oﬀers a window to admin-
ister pre-emptive therapy. To date, there is little data as to which kind
of treatment is preferred in case of molecular relapse (intensive rescue
chemotherapy, hypomethylating agents, transplant, donor-lymphocyte
infusion), and whether it could improve outcome. Sockel et al. reported
on a small series of MRD-positive NPM1+AML patients (n= 10) in 1st
and 2nd CR after intensive chemotherapy with or without autologous or
alloSCT, receiving pre-emptive therapy with azacytidine (Sockel et al.,
2011). After a median follow-up time of 10 months, 70% of them were
still in morphological CR (more than is expected from historical series)
and had MRD-response (at least 1-log decrease), however only tem-
porary for 4 of them. Moreover, Ragon et al. reported on 17 CBF-pa-
tients, who were MRD-positive at the start of maintenance with a hy-
pomethylating agent (HMA) after intensive chemotherapy: 12/17
remained in complete morphological remission, with molecular re-
sponse in 11/12 after 1 or 2 cycles (Ragon et al., 2017). In conclusion,
there seems to be some kind of sensitivity of low-level MRD-positive
good-risk AML to HMA therapy. However, there is no data on the eﬀect
of these kind of strategies on outcome, and randomized prospective
trials are lacking.
8. Conclusion
In conclusion, there is currently suﬃcient evidence that MRD eva-
luation has an added value in prognostication in non-APL AML, and
that it is more than just a surrogate marker for known risk factors.
Diﬀerent retrospective studies suggest that MRD might even overrule
known pre-treatment outcome predictors such as mutational status: as
such, the behavior of the disease during treatment might become
equally or even more important to decide whether or not an upgrade of
treatment (such as an alloSCT) is necessary to improve outcome.
However, there are still many open issues as to what the ideal time
point is to measure MRD, which threshold is clinically signiﬁcant, what
sample (peripheral blood or bone marrow) should be used and how we
can standardize tests so that results from diﬀerent labs become com-
parable. Moreover, survival beneﬁt of MRD-directed post-induction
treatment strategies needs to be conﬁrmed in prospective randomized
controlled trials, before MRD can be incorporated in clinical guidelines.
The same is true for pre-emptive therapy in molecular relapse. And of
course, all taking into account cost-eﬀectiveness of these strategies. We
expect MRD to be a major contributor in the process of clinical decision-
making for individual AML patients with regard to treatment and
follow-up in the (near) future.
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